We are live on
!
Find out more
QM
QVIDTVM Management Portfolio holdings
AUM
$76.6M
1-Year Est. Return
33.48%
This Fund
S&P 500
This Quarter
Est. Return
+35.5%
1 Year Est. Return
+33.48%
3 Year Est. Return
+19.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76.6M
AUM Growth
-$4.77M
(-5.9%)
Cap. Flow
-$19.2M
Cap. Flow
% of AUM
-25.12%
Top 10 Holdings %
Top 10 Hldgs %
99.22%
Holding
15
New
1
Increased
3
Reduced
10
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$3.27M |
| 2 |
Alexandria Real Estate Equities
ARE
|
+$2.03M |
| 3 |
AMRZ
Amrize Ltd
AMRZ
|
+$1.62M |
| 4 |
OCTV
Octave Intelligence
OCTV
|
+$1.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solventum
SOLV
|
+$12.9M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$4.96M |
| 3 |
Dentsply Sirona
XRAY
|
+$4M |
| 4 |
NBIS
Nebius Group N.V.
NBIS
|
+$2.38M |
| 5 |
Zegna
ZGN
|
+$904K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.86% |
| 2 | Communication Services | 17.54% |
| 3 | Materials | 17.21% |
| 4 | Technology | 12.12% |
| 5 | Consumer Discretionary | 7.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bio-Rad Laboratories Class A
BIO
$10.4B
| $19.4M | 25.39% |
66,243
-17,489
| -21% | -$4.96M |
|
|
NBIS
2
Nebius Group N.V.
NBIS
$57.3B
| $13.4M | 17.54% |
48,657
-12,021
| -20% | -$2.38M |
|
|
AMRZ
3
Amrize Ltd
AMRZ
$24.1B
| $13.2M | 17.21% |
247,391
+29,935
| +14% | +$1.62M |
|
|
4
Oracle
ORCL
$444B
| $8.35M | 10.9% |
56,970
+18,068
| +46% | +$3.27M |
|
|
5
Solventum
SOLV
$15.7B
| $6.87M | 8.97% |
89,033
-176,582
| -66% | -$12.9M |
|
|
6
Zegna
ZGN
$5.36B
| $5.93M | 7.75% |
455,804
-70,089
| -13% | -$904K |
|
|
7
Alexandria Real Estate Equities
ARE
$9.07B
| $4.36M | 5.69% |
82,470
+42,470
| +106% | +$2.03M |
|
8
BRC Inc
BRCC
$122M
| $3.28M | 4.28% |
295,314
-44,754
| -13% | -$554K |
|
|
OCTV
9
Octave Intelligence
OCTV
$5.36B
| $937K | 1.22% |
+57,466
| New | +$1.06M |
|
10
Wabtec
WAB
$47.4B
| $202K | 0.26% |
750
-2,020
| -73% | -$534K |
|
|
11
Dentsply Sirona
XRAY
$2.28B
| $201K | 0.26% |
18,929
-366,480
| -95% | -$4M |
|
12
Philip Morris
PM
$290B
| $186K | 0.24% |
1,026
-53
| -5% | -$9.19K |
|
13
Standard BioTools
LAB
$265M
| $183K | 0.24% |
222,000
-7,338
| -3% | -$6.93K |
|
14
H&R Block
HRB
$6.3B
| $32.1K | 0.04% |
844
-22,411
| -96% | -$781K |
|
15
Rentokil
RTO
$12.1B
| – | – |
-6,879
| Closed | -$217K |
|
Similar funds
SWM
MP
MA
PWS
SPC
SRA
BC
VIM
QVIDTVM Management's Q2 2026 Portfolio in Review
As of Q2 2026, QVIDTVM Management held 15 positions worth $76.6M, down 5.9% from $81.4M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
QVIDTVM Management withdrew a net $19.2M in Q2 2026, closing 1 position and reducing 10 holdings. Its most notable exit was Rentokil, an estimated $217K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 56% a quarter earlier, followed by Communication Services and Materials.
Against the trend, QVIDTVM Management opened a new position in Octave Intelligence worth $937K.
- QVIDTVM Management's largest Q2 2026 buy was Octave Intelligence: 57,466 shares worth $937K.
- QVIDTVM Management added most to Oracle in Q2 2026, an estimated $3.27M increase.
- QVIDTVM Management's biggest Q2 2026 reduction was Solventum, cutting an estimated $12.9M.
- QVIDTVM Management fully exited Rentokil in Q2 2026, selling an estimated $217K.
- QVIDTVM Management's ten largest holdings make up 99% of its $76.6M portfolio in Q2 2026.
- QVIDTVM Management opened 1 new position and closed 1 in Q2 2026.
- QVIDTVM Management's portfolio value fell 5.9% quarter-over-quarter to $76.6M.
Based on QVIDTVM Management's 13F filing for Q2 2026, filed 13 Aug 2026.